A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Studyto Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Duodenitis who have an Inadequate Response with, Lost Response to, or